Trial Profile

Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TRV 027 (Primary)
Indications Blood coagulation disorders; COVID 2019 infections
Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
Acronyms COVRAS

Most Recent Events

27 Nov 2022 Primary endpoint (Coagulopathy associated with COVID-19) has not been met according to results published in the British Journal of Clinical Pharmacology
27 Nov 2022 Results published in the British Journal of Clinical Pharmacology
30 Sep 2021 According to a Trevena media release, the company will host a conference call and webcast with the investment community on September 30, 2021, discussing results from this trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com